Ravi Viswanathan
CIK 1479386 · last filed 2022-02-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$21.85B
Companies
28
Total Filings
71
Lifetime Open-Market Net
$112.58M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DUOL | 10%+ Owner | 5,239,835 | $132.75 | $695.59M | $0 | 1 | 2022-02-16 |
| ESTC | 10%+ Owner | 1,528,117 | $64.04 | $97.86M | $0 | 1 | 2018-10-10 |
| ASND | 10%+ Owner | 82,978,668 | $247.73 | $20.56B | $49.02M | 4 | 2018-09-10 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | 10%+ Owner | 1,869,804 | $15.00 | $28.05M | $8.17M | 8 | 2018-08-22 |
| ARDX | 10%+ Owner | 3,082,186 | $5.01 | $15.46M | $23.33M | 3 | 2018-05-30 |
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 3,312,877 | $1.07 | $3.54M | $2.00M | 1 | 2018-04-23 |
| TESARO, Inc. (TSRO) Delisted | 10%+ Owner | 9,681,129 | — | — | $73.31M | 6 | 2018-03-06 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | 10%+ Owner | 0 | $28.80 | $0 | -$731.3K | 1 | 2018-02-27 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | 10%+ Owner | 10,882,574 | — | — | $0 | 1 | 2018-02-22 |
| APPN | 10%+ Owner | 1,523 | $26.91 | $41.0K | -$66.07M | 4 | 2018-02-15 |
| SYNLOGIC, INC. (SYBX) Delisted | 10%+ Owner | 281,929 | $0.69 | $194.5K | $0 | 2 | 2018-01-26 |
| Care.com Inc (CRCM) Delisted | 10%+ Owner | 2,256,013 | — | — | $0 | 2 | 2017-11-08 |
| RYTM | 10%+ Owner | 4,359,956 | $105.89 | $461.65M | $9.35M | 1 | 2017-10-10 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | 10%+ Owner | 325,606 | $29.08 | $9.47M | $15.00M | 1 | 2017-07-06 |
| MULESOFT, INC (MULE) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2017-03-22 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 5,215,128 | — | — | $6.75M | 1 | 2016-12-19 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 3,490,073 | — | — | $4.39M | 1 | 2016-10-31 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 321,681 | — | — | $4.60M | 3 | 2016-09-30 |
| Epizyme, Inc. (EPZM) Delisted | 10%+ Owner | 406,500 | $1.47 | $597.6K | $23.98M | 4 | 2016-01-12 |
| Avalo Therapeutics, Inc. (CERC.U) Delisted | 10%+ Owner | 594,245 | — | — | $0 | 1 | 2015-10-20 |
| SYNLOGIC, INC. (MIRN) Delisted | 10%+ Owner | 1,241,650 | — | — | $6.00M | 1 | 2015-10-06 |
| BOX | 10%+ Owner | 0 | $31.25 | $0 | $0 | 1 | 2015-01-29 |
| CVENT INC (CVT) Delisted | 10%+ Owner | 336 | $8.52 | $2.9K | -$46.25M | 5 | 2014-11-28 |
| DERM | 10%+ Owner | 3,433,810 | $6.55 | $22.49M | $1.11M | 1 | 2014-10-08 |
| Loxo Oncology, Inc. (LOXO) Delisted | 10%+ Owner | 1,789,420 | — | — | $3.00M | 1 | 2014-08-06 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 11,399 | $0.08 | $926 | $17.11M | 2 | 2013-06-05 |
| WDAY | 10%+ Owner | 0 | $157.11 | $0 | $0 | 2 | 2013-04-11 |
| Millennial Media Inc. (MM) Delisted | 10%+ Owner | 8,196,614 | — | — | -$21.48M | 2 | 2012-10-30 |
Recent Filings · Page 2 of 8
71 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-05-09 | — | Mixed | — | $0 | |
| 2018-04-23 | Surface Oncology, Inc. (SURF) Delisted | Mixed | +3,312,877 | $2.00M | EDGAR |
| 2018-04-10 | AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Buy (P) | +920,976 | $2.12M | EDGAR |
| 2018-03-28 | ASND | Buy (P) | +6,571,164 | $12.59M | EDGAR |
| 2018-03-23 | ASND | Buy (P) | +1,268,508 | $2.42M | EDGAR |
| 2018-03-13 | — | U | −10,882,574 | $0 | |
| 2018-03-06 | TESARO, Inc. (TSRO) Delisted | Buy (P) | +145,532 | $8.35M | EDGAR |
| 2018-02-27 | Oruka Therapeutics, Inc. (ABIO) Delisted | Sell (S) | −1,460,209 | -$731.3K | EDGAR |
| 2018-02-22 | Cascadian Therapeutics, Inc. (CASC) Delisted | Conv (C) | +1,818,000 | $6.00M | EDGAR |
| 2018-02-15 | APPN | Mixed | +1,523 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.